Information Provided By:
Fly News Breaks for November 6, 2019
Nov 6, 2019 | 21:04 EDT
Piper Jaffray analyst Joseph Catanzaro lowered his price target on Aerie Pharmaceuticals to $48 after its Q3 earnings miss and FY19 revenue guidance cut. The analyst is keeping his Overweight rating however, stating that the management's near-term expectations are becoming "more realistic". Catanzaro added that there is little to suggest a reversal in quarterly script trends observed for its glaucoma products Rhopressa and Rocklatan.
News For AERI From the Last 2 Days
There are no results for your query AERI